Huntingdon Life Sciences and Harlan Laboratories to Operate Under New Brand and Name
Huntingdon Life Sciences (HLS) and Harlan Laboratories have announced that the two companies will be rebranded to reflect the new integrated management structure that has been put in place and the broader product and service offerings of the combined organisations.
The new name and rebranding is a significant key milestone that will mark the beginning of a new period for both Harlan and HLS, following a history stretching back more than 80 years.
One of the world’s leading branding agencies helped inform the decision, following an extensive review of existing customer relationships, synergies across the two organisations and the projected outlook for the market sectors that they serve. A huge amount of internal integration work, both strategic and operational, has already been completed and the two companies will be formally merged under one brand in the coming months.
Two core business units of Research Model and Services (RMS) and Contract Research Services (CRS) have been established from existing capabilities across Harlan and HLS, as well as subsidiaries of both companies. The RMS business unit provides high-quality research models, lab animal diets and bedding, and support services from 30 sites worldwide. The CRS business unit offers a comprehensive range of drug development and environmental sciences services, including safety assessment, analytical, metabolism, CMC, and regulatory consultancy from nine contract research facilities within Europe, the US and the Middle East.
Throughout this process, both companies have kept customer relationships as the central consideration, and the new company will be able to deliver a far broader range of products and services to their customers from more global locations.
Brian Cass, CEO, commented: “The decision to rebrand the two companies as one entity is the natural progression of a sustained integration process that was put in place last year. It is a symbol of the fact that as one integrated company we are now able to further diversify the range of products and services we can provide to the market, further supporting existing relationships whilst growing our business globally with new customers. It’s a hugely exciting time for our company, with our customer-led focus and flexibility in approach, our goal is to establish our new company as the number one development partner for customer service and scientific expertise.”
Related News
-
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharma Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance